(Ultra-)low dosing of rituximab in rheumatoid arthritis: chances and challenges.
作者信息
den Broeder Alfons A, den Broeder Nathan, Verhoef Lise M
机构信息
Department of Rheumatology, Sint Maartenskliniek, Ubbergen, The Netherlands.
出版信息
Rheumatol Adv Pract. 2021 Feb 4;5(1):rkab007. doi: 10.1093/rap/rkab007. eCollection 2021.
Abstract
摘要
相似文献
1
(Ultra-)low dosing of rituximab in rheumatoid arthritis: chances and challenges.类风湿关节炎中（超）低剂量利妥昔单抗：机遇与挑战
Rheumatol Adv Pract. 2021 Feb 4;5(1):rkab007. doi: 10.1093/rap/rkab007. eCollection 2021.
2
Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial.类风湿关节炎中超低剂量利妥昔单抗：一项随机对照试验的研究方案
Trials. 2017 Aug 30;18(1):403. doi: 10.1186/s13063-017-2134-x.
3
[Rituximab in patients with rheumatoid arthritis: systematic review].[利妥昔单抗治疗类风湿关节炎患者：系统评价]
Orv Hetil. 2007 Oct 7;148(40):1883-93. doi: 10.1556/OH.2007.28080.
4
Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial.利妥昔单抗（抗CD20单克隆抗体）在类风湿关节炎患者II期临床试验中的群体药代动力学。
J Clin Pharmacol. 2005 Jul;45(7):792-801. doi: 10.1177/0091270005277075.
5
Rituximab for rheumatoid arthritis-associated large granular lymphocytic leukemia, a retrospective case series.利妥昔单抗治疗类风湿关节炎相关的大颗粒淋巴细胞白血病：一项回顾性病例系列研究。
Semin Arthritis Rheum. 2020 Oct;50(5):1109-1113. doi: 10.1016/j.semarthrit.2020.05.020. Epub 2020 Jun 16.
6
Severe infection in patients with rheumatoid arthritis taking anakinra, rituximab, or abatacept: a systematic review of observational studies.使用阿那白滞素、利妥昔单抗或阿巴西普的类风湿关节炎患者的严重感染：观察性研究的系统评价
Rev Bras Reumatol Engl Ed. 2016 Nov-Dec;56(6):543-550. doi: 10.1016/j.rbre.2016.10.001. Epub 2016 Oct 27.
7
Rituximab as a treatment option in a patient with rheumatoid arthritis and a history of malignancy-intracranial chondrosarcoma/osteochondroma-case based review.利妥昔单抗作为一名类风湿关节炎合并恶性病史（颅内软骨肉瘤/骨软骨瘤）患者的治疗选择——病例回顾
Rheumatol Int. 2021 Feb;41(2):463-468. doi: 10.1007/s00296-020-04706-1. Epub 2020 Oct 1.
8
A comprehensive review of rituximab therapy in rheumatoid arthritis patients.类风湿关节炎患者利妥昔单抗治疗的全面综述。
Clin Rheumatol. 2019 Nov;38(11):2977-2994. doi: 10.1007/s10067-019-04699-8. Epub 2019 Aug 1.
9
Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.类风湿关节炎初始 TNFi 治疗失败后应用替代肿瘤坏死因子抑制剂（TNFi）或阿巴西普或利妥昔单抗：SWITCH RCT。
Health Technol Assess. 2018 Jun;22(34):1-280. doi: 10.3310/hta22340.
10
Management of acute HVE infection in a patient treated with rituximab for rheumatoid arthritis.
Joint Bone Spine. 2016 Oct;83(5):577-8. doi: 10.1016/j.jbspin.2015.11.010. Epub 2016 Apr 4.
引用本文的文献
1
Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trial.类风湿关节炎中超低剂量利妥昔单抗的长期临床和放射学疗效及安全性：REDO 试验的观察性扩展。
RMD Open. 2024 Apr 9;10(2):e003659. doi: 10.1136/rmdopen-2023-003659.
2
To flare or not to flare: patients' and rheumatologists' perceptions on the on-flare retreatment strategy of rituximab in rheumatoid arthritis.是否复发：患者及风湿病学家对类风湿关节炎中利妥昔单抗复发再治疗策略的看法
Ther Adv Musculoskelet Dis. 2024 Feb 28;16:1759720X241232268. doi: 10.1177/1759720X241232268. eCollection 2024.
本文引用的文献
1
Low-dose rituximab protocol in rheumatoid arthritis-outcome and economic impact.类风湿关节炎的低剂量利妥昔单抗方案——疗效与经济影响
Rheumatol Adv Pract. 2021 Jan 7;5(1):rkaa077. doi: 10.1093/rap/rkaa077. eCollection 2021.
2
Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab.接受利妥昔单抗治疗的炎症性风湿疾病患者发生重症新型冠状病毒肺炎的风险增加。
Ann Rheum Dis. 2021 May;80(5):e67. doi: 10.1136/annrheumdis-2020-218075. Epub 2020 Jun 26.
3
Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event.利妥昔单抗治疗风湿性疾病后进展性多灶性白质脑病：罕见事件。
J Neurovirol. 2018 Jun;24(3):323-331. doi: 10.1007/s13365-018-0615-7. Epub 2018 Mar 5.
4
Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection.类风湿关节炎再治疗时的利妥昔单抗剂量：对维持治疗和严重感染风险的影响。
Rheumatology (Oxford). 2018 Mar 1;57(3):538-547. doi: 10.1093/rheumatology/kex446.
5
Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis.类风湿关节炎患者使用生物制剂和靶向药物的严重不良反应风险：一项系统评价和荟萃分析
Rheumatology (Oxford). 2017 Mar 1;56(3):417-425. doi: 10.1093/rheumatology/kew442.
6
Updated systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis.比较低剂量与高剂量利妥昔单抗治疗类风湿关节炎的随机对照试验的更新系统评价和荟萃分析
Clin Rheumatol. 2015 Oct;34(10):1801-5. doi: 10.1007/s10067-015-2977-z. Epub 2015 Jun 12.
7
Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.22例接受B淋巴细胞清除治疗的类风湿关节炎患者的临床结局
Ann Rheum Dis. 2002 Oct;61(10):883-8. doi: 10.1136/ard.61.10.883.
Zotero 插件